Abrocitinib vs. Dupilumab will be an important question for many prescribing doctors with the expected FDA approval of abrocitinib soon. We have extensively discussed atopic dermatitis (eczema) in the past. For many years only topical therapies were available for this condition. Topical steroids are the mainstays of treatment, and after many years newer topical therapies […]
Baricitinib for Atopic Dermatitis (Eczema)
Baricitinib is currently being studied for the treatment of atopic dermatitis. Baricitinib is part of the family of oral Janus kinase inhibitors that are an emerging modality in the treatment of chronic allergic inflammatory disorders due to their ability to inhibit signaling of multiple pathways of cytokines. We discussed in another blog post, Abrocitinib which is […]
Omalizumab for Atopic Dermatitis
Omalizumab for atopic dermatitis has shown promising results. In JAMA Pediatrics, the researchers have demonstrated for the first time that omalizumab, which neutralizes IgE, reduced disease severity and improved quality of life in pediatric patients with severe atopic dermatitis. This was the case even in subjects with very high baseline total plasma IgE levels. Omaizumab […]
Ruxolitinib for Eczema (atopic dermatitis)
Ruxolitinib is a new medication being studied for the treat of eczema. Ruxolitinib is a selective inhibitor of Janus kinase 1 and Janus kinase 2, it potently suppresses cytokine signaling involved in atopic dermatitis pathogenesis. We discussed the Janus Kinase pathway in a previous post and how new drugs are being developed for the treatment […]
New treatments for eczema on the horizon
Eczema is an inflammatory skin disease that results in a rash and itching. This impacts a patients quality of life including depression, sleep disturbances and even suicidal ideation. Treatments include, moisturizers, topical steroids and calineurin inhibitiors. Despite treatment, many patients still suffer. Advances in recent years have brought new medications, Dupilumab and Eucrisa. Although they […]
Delgocitinib for patients with atopic dermatitis
Topical delgocitinib (JTE-052) is a novel Janus kinase inhibitor that has been shown to be effective in adults with eczema. Eczema is an itchy, inflammatory skin rash that lasts chronically and it can fluctuate. It is seen more in childhood and the majority of patients experience resolution with age. The goal of treatment is to […]
Adult Eczema a common problem
Adult eczema rates are greater than previously thought, but the frequency and characteristics of adult onset disease remain controversial. Atopic dermatitis or eczema is the leading cause of skin related disability, but most studies focus only on children. Eczema is common in adults, but it is not known whether the higher rates are from new […]
Adult Eczema: A Clinical Review
Approximately 1 in 4 adults report the onset of adult eczema and the rest its onset is from childhood. Eczema is an ill-defined skin lesions and it includes patches, papules, and plaques with different degrees of redness and swelling. It can affect any skin site but they most classically affect the creases of the elbows […]
Fezakinumab an IL-22 antagonist for Eczema
IL-22 upregulation characterizes atopic dermatitis lesions. However, blocking IL-22 has not been defined in human subjects. A recent study sought to evaluate the cellular and molecular effects of fezakinumab (anti-IL-22) versus placebo taken from biopsy specimens. Atopic dermatitis is the most common chronic inflammatory skin disease with increasing prevalence. IL-4 and IL-13 are the 2 […]
Tralokinumab for Atopic Dermatitis
Tralokinumab is a fully human monclonal antibody that potently and specifically neutralizes IL-13. IL-13 has an important role in atopic dermatitis pathogenesis. Atopic dermatitis (eczema) is a chronic inflammatory skin disease. It can affect sleep, psychosocial activities and health related quality of life. The symptoms of many patients are not controlled with current treatment regimens. […]